EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. - Wikidata - awgldk - TriplyDB

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

http://www.wikidata.org/entity/Q44200074

about

Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept.Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions Clinical management of grade III oligodendroglioma Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies Minimally invasive surgery of the anterior skull base: transorbital approaches Image-Guided Radiotherapy Using a Modified Industrial Micro-CT for Preclinical Applications Prospects of immune checkpoint modulators in the treatment of glioblastoma Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?Serum-Induced Differentiation of Glioblastoma Neurospheres Leads to Enhanced Migration/Invasion Capacity That Is Associated with Increased MMP9 Overcoming therapeutic resistance in glioblastoma: the way forward Brain tumors in Sweden: data from a population-based registry 1999-2012.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion.Immune Checkpoint in Glioblastoma: Promising and Challenging Assessment of accessibility to the diagnosis and treatment of brain tumors in Argentina: Preliminary results.Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells.Antiangiogenic therapy for glioblastoma: current status and future prospects.Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.International Differences in Treatment and Clinical Outcomes for High Grade Glioma Transforming growth factor-β pathway activity in glioblastoma.Psychiatric symptoms in glioma patients: from diagnosis to management.Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.Absence of human cytomegalovirus infection in childhood brain tumors.The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma Enhancing Predicted Efficacy of Tumor Treating Fields Therapy of Glioblastoma Using Targeted Surgical Craniectomy: A Computer Modeling Study Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.Unilateral malignant optic glioma following glioblastoma multiforme in the young: a case report and literature review The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2.Surgical Ventricular Entry is a Key Risk Factor for Leptomeningeal Metastasis of High Grade Gliomas Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study.Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial Control of glioma cell migration and invasiveness by GDF-15 A systematic pipeline for the objective comparison of whole-brain spectroscopic MRI with histology in biopsy specimens from grade III glioma.Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo

P2860

Q26774997-868F4631-C003-44FA-86F3-ED15179A7513 Q26795767-5A2D5B0B-9FF3-4F0E-B4AC-E5C0819B90F4 Q26801254-F63640A4-C577-4C90-BB1B-5C0B739611D9 Q26801351-4F6CF4E7-D698-455D-83AE-9A99F34F74DD Q26852366-145887ED-4A89-49EC-83D1-8AF587D4CC92 Q26865288-10315E74-5EFA-43AC-8C40-DFEF80ACDF8F Q27307856-D75F0CA2-12B6-4913-9E60-1416B99DE1C1 Q28081371-9A1042E5-78ED-42BB-A3B5-1BA90AC9FC3D Q28084351-30165813-19CB-4C10-8E24-6DE6DC898529 Q28551757-BE722436-9741-45D6-B618-A1612F5D6C47 Q29248396-C822B4A0-03F5-4105-AEC0-F755123EF9B1 Q30868551-EBC0C051-E8B6-40DA-961E-74A95600388C Q33419628-86D79F49-765A-4D9F-9762-B96E80577C16 Q33436238-83518DC4-966C-4FF1-9F5B-36BC2D4717EC Q33439379-882DB9ED-1068-446D-92B6-29494B9384D5 Q33615176-F1196DA8-55A1-40EC-8980-096F6F1828A8 Q33650058-05AA6848-25D0-4493-9BC9-FCEEF655ACE0 Q33828229-A7790AC8-AA35-46F5-A8AF-6C242A58D2FB Q34484456-E6B7D300-E1DC-4D65-AF46-2549C58CBB09 Q34523319-77FD8AE9-D812-4B53-8B8F-81A00B321E36 Q34982039-288C8F3E-BCD2-4AB8-8F58-1462D5489CA4 Q35659472-019AC09F-43D0-4563-B95C-A315E3398530 Q35742442-27F06D57-8FAB-4092-9BDC-767645856E0B Q35743504-3508E5B5-001F-472F-96F3-52FE9BB6F02D Q35955393-A868DEBC-A288-4E48-A339-5ED7A7C8C188 Q36008323-E3BE1E9E-6A00-43D9-9A4D-5BB0D1C23455 Q36057137-E3FB0696-D172-4208-A6E5-0A3C8D01F042 Q36118131-98463633-3D4D-41F8-BAD8-7A627D60A658 Q36151109-44153440-5B3B-4F79-B787-CDC78E0A9D9E Q36164058-D2DA4AFD-17E2-47CC-AB36-2BCD209D2234 Q36305127-3E53C888-B272-4BF6-BAE6-2A2D09B4B628 Q36332448-684F56AF-2805-4BCD-9D9C-14A36D757D8A Q36346166-A1C74A1F-927A-4F6D-9462-4F63953ABB5D Q36399129-6A08631B-8B9C-435B-ABCC-177D264F2039 Q36421110-6EE392A6-C605-43DC-BFE3-4A7C580AE065 Q36676389-B541A303-DCC1-4288-AD2B-A212B0BCF32C Q36705933-0147F619-7F82-455F-9B2E-01D6392AA761 Q36946604-B5FBCF9F-4523-4118-84CD-FA8F505327AE Q37143167-48DA310A-C067-408C-8765-488039F387F3 Q37207348-6B7066E3-BF20-4B8F-951F-4DA274D7C467

P2860

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

http://www.wikidata.org/entity/Q44200074

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@en

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@nl

type

label

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@en

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@nl

prefLabel

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@en

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

@nl

P1433

Q44200074-0C154248-6D35-4CE6-B478-FC89BE8A5F6F

P1476

Q44200074-7B0B3412-CC30-4DE4-897C-9275EAB0336D

P2093

Q44200074-0BDE9D81-B2B8-481A-8526-4D6A09D106BA

Q44200074-1172225D-DA60-4F7B-84B3-70C1042E4928

Q44200074-15F0827E-9DBF-4497-ADF4-3EEB5CD1CCEE

Q44200074-2A24A847-9787-4759-BE98-00C17B767545

Q44200074-2B8F5605-10DA-4ECA-9B10-2DF38FAAEDAC

Q44200074-2BF59F58-629E-453F-AE82-383E89D176C6

Q44200074-354E1D00-D8A7-467C-A358-5DDA3E6CB8B4

Q44200074-3DAC2580-A9F9-4A49-8EB7-5A9E77390735

Q44200074-3F05D222-1920-4F06-89D6-853E1932BE1B

Q44200074-8F536823-BE60-45D5-8BD2-80EA9C32E1AD

P304

Q44200074-9A89BF69-7EFD-4188-B1C8-6AFD9C39C9DF

P31

Q44200074-FAA1B59D-DF10-4D23-A6A8-00F435C32AEA

P356

Q44200074-0E1DD139-E32F-4904-9801-5A01C62987F7

P433

Q44200074-3C045220-BACE-41CB-8855-275845607290

P478

Q44200074-660D4A10-1F41-4E17-B2D0-1120A9C08DE2

P50

Q44200074-2C5C4D8C-41A3-4B4F-998C-D328F0A2C4B6

Q44200074-63D56376-6525-475E-9110-43745B9F191D

Q44200074-6C2E242F-AB19-46CE-9C4E-21FEAA269241

Q44200074-7978DA63-755C-4FCC-881E-9198710943A1

P577

Q44200074-1639547E-094E-46C6-B867-1C0CC3E33E58

P698

Q44200074-558C7B03-40CA-4A62-B798-02BEA603405A

P356

S1470-2045(14)70011-7

P1433

The Lancet Oncology

P1476

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

@en

P2093

Didier Frappaz

http://www.w3.org/2001/XMLSchema#string

Elizabeth Cohen-Jonathan-Moyal

http://www.w3.org/2001/XMLSchema#string

European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma

http://www.w3.org/2001/XMLSchema#string

Guido Reifenberger

http://www.w3.org/2001/XMLSchema#string

Jörg C Tonn

http://www.w3.org/2001/XMLSchema#string

Kirsten Hopkins

http://www.w3.org/2001/XMLSchema#string

Michael Weller

http://www.w3.org/2001/XMLSchema#string

Riccardo Soffietti

http://www.w3.org/2001/XMLSchema#string

Roger Henriksson

http://www.w3.org/2001/XMLSchema#string

Roger Stupp

http://www.w3.org/2001/XMLSchema#string

P304

e395-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(14)70011-7

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Martin J van den Bent

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25079102

http://www.w3.org/2001/XMLSchema#string